All posts
-
BHP reports lowest profit since start of pandemic
Miner’s worst efficiency since 2020 pushed by falling iron ore and coal costs
-
Video Friday: Dance With CHILD
Video Clip Friday is your once a week choice of outstanding robotics video clips, accumulated by your good friends at IEEE Range robotics. We additionally publish an once a week sc…
-
Robots That Learn to Fear Like Humans Survive Better
This article is part of our exclusive IEEE Journal Watch series in partnership with IEEE Xplore. Imagine walking downtown when you hear a loud bang coming from the construction sit…
-
15 Questions Your Customers Will Ask When Buying Turnkey Robotic Solutions
As a company of complete robot options … what concerns might hold your consumers back from acquiring your options? If you have actually mostly used combination solutions in t…
-
Vision AI is Transforming Automated Optical Inspection | RoboticsTomorrow
Imaginative and prescient AI is Reworking Computerized Optical Inspection BitFlow and Advantech are teaming up to invent industry-main systems to make stronger quality, decrease atomize, and develop yield WOBURN, MA, AUGUST https://www.roboticstomorrow.com/info/2025/08/18/imaginative and prescient-ai-is-transforming-automatic-optical-inspection/25327/18, 2025 — Within the relentless pursuit for shut to-zero defects per million (DPM), many manufacturers are turning to Industrial Imaginative and
-
Leo Pharma CEO: Phone ringing off the hook since big deals with Gilead and Boehringer
Leo Pharma presently has around DKK 4bn in cash money, prepared to invest ought to the chance emerge.
-
Prelude to Coloplast’s quarterly results: Slight progress expected while US tariffs remain a key issue
Development is especially gotten out of Coloplast’s urology company.
-
Leo Pharma is one step closer to its 2025-goal – CEO sees no obstacles on the road to the stock market
Leo Pharma published a revenue of DKK 235m (USD 36.79 m) in the 2nd quarter of 2025. This follows a number of years of considerable losses.
-
US FDA approves Novo Nordisk’s Wegovy for the treatment of fatty liver disease
According to Novo Nordisk, the firm is the very first to have actually a medicine authorized for the therapy of fatty liver illness in the United States.
-
Novo Nordisk notes great potential for Wegovy in new US MASH market
The Danish drugmaker keeps particular numbers on market capacity, however the business is the very first to provide GLP-1 to deal with fatty liver that affects 5% of the United Sta…
